Dr. Greg Marchand Named to the Fulbright Specialist Roster by the U.S. Department of State
FOR IMMEDIATE RELEASE
MESA, Ariz. — September 12, 2021
Dr. Marchand is pleased to announce that his breakthrough paper, “A Systematic Review and Meta-Analysis of Intraperitoneal Bupivacaine in Laparoscopic Gynecologic Surgery” has been published in this month’s Journal of Pain Research. We are extremely excited about this new paper and the strong evidence it presents for the instillation of bupivacaine in the abdominal cavity at time of laparoscopic surgery (as opposed to subcutaneous use or nerve blockade.) Jokingly at the institute we reference that perhaps the bartender had it right all along – just pour it in!
You can find the full text of the paper online at pubmed, pubmed central, or on the journal website.
About Dr. Greg Marchand
Greg J. Marchand, MD, FACS, FACOG, FICS, is a dual board-certified obstetrician-gynecologist and minimally invasive gynecologic surgeon practising in Mesa, Arizona. He holds the ABOG Focused Practice Designation in Minimally Invasive Gynecologic Surgery and directs the Marchand Institute for Minimally Invasive Surgery, a 501(c)(3) tax-exempt non-profit research and educational corporation (EIN 42-2857240). He is Program Director of an SLS-accredited fellowship in Minimally Invasive and Robotic Gynecologic Surgery, holds three issued United States patents, and has served as Principal Investigator on eight FDA clinical trials. His systematic reviews are prospectively registered with PROSPERO, reported to PRISMA standards and appraised with the Cochrane Risk of Bias 2 tool. He accepts no industry funding for his research.
Media Contact
Maria A. Sainz
Director of Communications and Media Relations
maria@marchandobgyn.com
(480) 999-0905
Newsroom and press kit · Full publication list · Research methodology · Expert commentary topics
###
Related posts
